Whittier Trust Co. Has $46.47 Million Position in Johnson & Johnson (JNJ)

Share on StockTwits

Whittier Trust Co. increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.8% during the first quarter, according to its most recent filing with the SEC. The fund owned 362,596 shares of the company’s stock after buying an additional 6,356 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of Whittier Trust Co.’s portfolio, making the stock its 9th largest holding. Whittier Trust Co.’s holdings in Johnson & Johnson were worth $46,467,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Stifel Financial Corp lifted its holdings in Johnson & Johnson by 6,715.9% during the third quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after purchasing an additional 2,534,918 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Johnson & Johnson by 55.1% during the fourth quarter. Mackenzie Financial Corp now owns 4,243,594 shares of the company’s stock valued at $592,915,000 after purchasing an additional 1,507,278 shares during the last quarter. Cornerstone Investment Partners LLC lifted its holdings in Johnson & Johnson by 91.4% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,512,352 shares of the company’s stock valued at $211,306,000 after purchasing an additional 722,113 shares during the last quarter. Millennium Management LLC lifted its holdings in Johnson & Johnson by 122.0% during the fourth quarter. Millennium Management LLC now owns 1,009,912 shares of the company’s stock valued at $141,105,000 after purchasing an additional 555,038 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Johnson & Johnson by 4.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 12,576,360 shares of the company’s stock valued at $1,757,159,000 after purchasing an additional 551,632 shares during the last quarter. 65.97% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson opened at $122.00 on Friday, Marketbeat Ratings reports. The company has a current ratio of 1.58, a quick ratio of 1.25 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $326.27 billion, a P/E ratio of 16.71, a P/E/G ratio of 1.86 and a beta of 0.73. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. Johnson & Johnson’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.83 earnings per share. sell-side analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.95%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Friday, May 25th. Johnson & Johnson’s dividend payout ratio is 49.32%.

Several research firms have commented on JNJ. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a report on Wednesday. They set a “market perform” rating and a $129.00 price objective on the stock. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b” rating in a report on Friday, May 18th. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Finally, Citigroup lowered their price target on shares of Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a report on Monday, April 23rd. Six analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $141.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply